Impact of a lifestyle program on vascular insulin resistance in metabolic syndrome subjects: the RESOLVE study

J Clin Endocrinol Metab. 2015 Feb;100(2):442-50. doi: 10.1210/jc.2014-2704. Epub 2014 Oct 29.

Abstract

Context and objective: Impaired insulin-dependent vasodilation might contribute to microvascular dysfunction of metabolic syndrome (MetS). The aims of this study were to assess the insulin vasoreactivity in MetS, and to evaluate the effects of a lifestyle program. DESIGN, SETTING, PARTICIPANTS, AND OUTCOME MEASURES: Laser Doppler measurements were used to assess cutaneous blood flux (CBF) and flowmotion in response to iontophoresis of insulin and acetylcholine (ACh) in 38 MetS and 18 controls. Anthropometric, plasma insulin, glycemia, and inflammatory markers were measured. MetS subjects (n = 24) underwent a 6-month lifestyle intervention (M6) with a 3-week residential program (D21).

Results: The absolute and relative peak insulin and ACh CBF were significantly higher in controls than in MetS subjects. Significant inverse correlations were found between peak insulin CBF and glycemia, insulin and glycated hemoglobin, active plasminogen activator inhibitor-1 (PAI-1), C-reactive protein (CRP), and IL-6. With respect to flowmotion, MetS subjects showed lower values in total spectrum CBF and in all its components (except respiratory one). At D21 and M6, peak insulin CBF increased and was no longer different from control values whereas peak ACh CBF did not change. From D21, all the different components and the total CBF spectrum became similar to the control values. The changes in peak insulin CBF and in endothelial component between M6 and baseline were inversely correlated with the change in CRP and PAI-1.

Conclusions: The local vasodilatory effects to insulin and its overall flowmotion are impaired in MetS subjects in relation to inflammation. The lifestyle intervention reversed this insulin-induced vascular dysfunction in parallel to decreased inflammation level.

Trial registration: ClinicalTrials.gov NCT00917917.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Blood Glucose / metabolism
  • C-Reactive Protein / metabolism
  • Female
  • Health Promotion*
  • Humans
  • Insulin / blood
  • Insulin Resistance / physiology*
  • Interleukin-6 / blood
  • Life Style*
  • Male
  • Metabolic Syndrome / blood
  • Metabolic Syndrome / physiopathology
  • Metabolic Syndrome / therapy*
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / blood
  • Regional Blood Flow / physiology
  • Vascular Resistance / physiology

Substances

  • Blood Glucose
  • Insulin
  • Interleukin-6
  • Plasminogen Activator Inhibitor 1
  • C-Reactive Protein

Associated data

  • ClinicalTrials.gov/NCT00917917